Evidence map›Paper›PMID 26690680›Full record

ReviewWorld journal of gastrointestinal oncology2015

Minimally invasive surgical approach to pancreatic malignancies.

Lapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastrointestinal oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lapo BenciniLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Mario AnnecchiaricoLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Marco FarsiLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Ilenia BartoliniLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Vita MirasoloLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Francesco GuerraLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Andrea CorattiLapo Bencini, Mario Annecchiarico, Marco Farsi, Ilenia Bartolini, Vita Mirasolo, Francesco Guerra, Andrea Coratti, Department of Oncology, Division of Surgical Oncology and Robotics, Careggi University Hospital, 50131 Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITCreative Research Enterprises (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic surgery for malignancy is recognized as challenging for the surgeons and risky for the patients due to consistent perioperative morbidity and mortality. Furthermore, the oncological long-term results are largely disappointing, even for those patients who experience an uneventfully hospital stay. Nevertheless, surgery still remains the cornerstone of a multidisciplinary treatment for pancreatic cancer. In order to maximize the benefits of surgery, the advent of both laparoscopy and robotics has led many surgeons to treat pancreatic cancers with these new methodologies. The reduction of postoperative complications, length of hospital stay and pain, together with a shorter interval between surgery and the beginning of adjuvant chemotherapy, represent the potential advantages over conventional surgery. Lastly, a better cosmetic result, although not crucial in any cancerous patient, could also play a role by improving overall well-being and patient self-perception. The laparoscopic approach to pancreatic surgery is, however, difficult in inexperienced hands and requires a dedicated training in both advanced laparoscopy and pancreatic surgery. The recent large diffusion of the da Vinci(®) robotic platform seems to facilitate many of the technical maneuvers, such as anastomotic biliary and pancreatic reconstructions, accurate lymphadenectomy, and vascular sutures. The two main pancreatic operations, distal pancreatectomy and pancreaticoduodenectomy, are approachable by a minimally invasive path, but more limited interventions such as enucleation are also feasible. Nevertheless, a word of caution should be taken into account when considering the increasing costs of these newest technologies because the main concerns regarding these are the maintenance of all oncological standards and the lack of long-term follow-up. The purpose of this review is to examine the evidence for the use of minimally invasive surgery in pancreatic cancer (and less aggressive tumors), with particular attention to the oncological results and widespread reproducibility of each technique.

Indexed as

Da VinciLaparoscopicNeuroendocrine pancreatic tumorsPancreatic adenocarcinomaPancreatic cancerRobotic

Identifiers

PMID26690680
PMCPMC4678388
OpenAlexW2395517660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.